Bluecrest Wellness Cancer screening

Male Cancer Risk (over 40s)

A wide cancer-risk and general health screen for men over 40, including a PSA prostate cancer risk test alongside bowel, stomach, liver, kidney and lung function checks.

  • Doctor reviewed
  • Male
Sample
Mixed
Collection
Venous draw at local venue plus at-home self-collection kit(s)
Results in
3–8 days
Biomarkers
34
Doctor reviewed
Yes
Tests for
  • Blood Health Markers
  • Bone Health, Energy & Muscles
  • Bowel Cancer Risk (qFIT test)
  • Cholesterol & Advanced Diabetes
  • Essential Proteins and Iron
  • Immune System
  • Kidney Function
  • Liver Function
  • Lung Function Check for COPD
  • Prostate Cancer Risk (PSA)
  • Stomach Cancer Risk (H Pylori)
  • Urinalysis

Test specifications

Provider
Bluecrest Wellness
Sample type
mixed
Collection method
venous draw at local venue plus at-home self-collection kit(s)
Turnaround time
3–8 days
Biomarkers tested
34
At-home test
No
Doctor reviewed
Yes
Gender focus
Male

What's tested

12 biomarkers as listed by Bluecrest Wellness, of 34 in total.

  • Blood Health Markers
  • Bone Health, Energy & Muscles
  • Bowel Cancer Risk (qFIT test)
  • Cholesterol & Advanced Diabetes
  • Essential Proteins and Iron
  • Immune System
  • Kidney Function
  • Liver Function
  • Lung Function Check for COPD
  • Prostate Cancer Risk (PSA)
  • Stomach Cancer Risk (H Pylori)
  • Urinalysis

About this test

The Male Cancer Risk package is aimed at men aged 40 and over (or younger with a strong family history of prostate cancer) and combines tests that may flag signs associated with bowel, prostate, bladder and blood cancers, specifically a qFIT bowel cancer risk test and a PSA prostate cancer risk test, plus an H. pylori stomach cancer risk test, alongside 34 biomarkers covering blood health, bone health, cholesterol, kidney and liver function, lung function and urinalysis. Bluecrest is explicit that these tests are not diagnostic on their own, and specifically flags that you should read the guidance on the benefits and limitations of PSA testing before choosing this package.

At 34 biomarkers, this places in the 86th percentile for clinical depth among the cancer screening tests we track. As with the Female Cancer Risk package, there is no directly comparable package in our data to benchmark the £319 price against.

Results and follow-up score well here, because this package includes a doctor review and a private GP consultation by phone or webcam, plus access to Perci Health's specialist cancer nursing support if a cancer-risk result comes back amber or red.

Who is it for?

This suits men aged 40 and over who want a wide screen across several cancer-risk areas, including prostate cancer risk, alongside a general health check, and who value a GP consultation to discuss the results. Bluecrest recommends against this package under 40 unless you have a close relative diagnosed with prostate cancer before age 50, in which case it may be worth considering earlier. If your main interest is heart disease and stroke risk, the Male Cancer Risk + Complete version adds an ECG, peripheral arterial disease check and Lipoprotein(a) test for £519 total.

How it works

Collection is mixed: a venous blood draw at a local Bluecrest venue, alongside at-home self-collection kits for tests such as the bowel cancer risk marker. Results are typically returned in around 3 to 8 days. Results are reviewed by a doctor, with a private consultation by phone or webcam, and Bluecrest advises reading its PSA testing guidance beforehand given the test's known limitations.

Pros & cons

Pros

  • Includes a PSA prostate cancer risk test alongside bowel and stomach cancer risk markers.
  • Includes a doctor review and private GP consultation, unlike most individual Bluecrest tests.
  • Covers 34 biomarkers across cancer-risk and general health in one package.
  • Access to Perci Health cancer nursing support if a cancer-risk result is amber or red.

Cons

  • Not recommended for men under 40, other than those with a strong family history of prostate cancer.
  • No comparable package in our data to check whether £319 is good value.
  • PSA testing has known limitations that Bluecrest asks you to read about before choosing this package.

Our editorial score

Compare Health Test Score Men's cancer-risk screen adding a PSA prostate test
Editorial confidence: 10.0/10

This £319 package for men over 40 combines cancer-risk markers, including a PSA prostate cancer test, bowel (qFIT) and stomach (H. pylori) risk tests, with a wider health check across 34 biomarkers covering liver, kidney and lung function. There's no comparable package in our data to benchmark the price against, but results here are reviewed by a doctor, unlike most of Bluecrest's individual tests.

Score breakdown

  • Clarity and documentation 8.0/10

    The listing publishes a detailed description, some of the biomarkers by name, a stated turnaround, clear collection options, the sample type; it does not state what the report looks like.

  • Clinical depth 9.6/10

    34 biomarkers, placing it in the 86th percentile of cancer screening tests we track.

  • Collection convenience 7.0/10

    A finger-prick sample you take at home; with a venous or clinic option as well; results in around 8 days, slower than similar tests.

  • Results and follow-up 7.0/10

    Results are reviewed by a doctor; the provider does not describe the report format.

  • Trust signals 9.5/10

    Trustpilot 4.7 from 6,787 reviews; accredited lab (UKAS ISO 15189 own lab); CQC registered; trading 14+ years.

  • Value for money 6.0/10

    £319.00; no comparable tests to benchmark against yet.

Calculated 13 September 2026 from the facts we hold about this test and provider, using our published scoring formula. Scores are not hand-edited.

More in Cancer screening

View all →
Selph

qFIT Bowel Cancer Screening Test

Priced close to the FIT test group median

A stool test using the qFIT method to measure blood in a stool sample, giving a numerical result rather than a simple positive or negative. Suited to adults wanting to check a common early indicator of possible bowel cancer risk.

  • At-home test
8.1 / 10
£59.00
Full review →